A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Imsidolimab (Primary)
- Indications Palmoplantar pustulosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms POPLAR
- Sponsors AnaptysBio
- 05 May 2022 Status changed from discontinued to completed.
- 13 May 2021 This trial has been completed in Germany (End Date: 23 Apr 2021), according to European Clinical Trials Database record.
- 08 Mar 2021 According to an Anaptys Bio media release, does not currently plan to conduct further clinical development of imsidolimab in PPP